All stock lists
RenovoRx, Inc. (NASDAQ:RNXT)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.29+0.00 (+0.39%)
Insider Score
––Not scored
RNXT Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
RNXT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 909.00 K | 563.00 K | 238.00 K | 266.00 K | 422.00 K | 197.00 K |
| Revenue Growth (YoY) | 115.40 % | 185.79 % | 453.49 % | — | — | — |
| Cost of Revenue | 143.00 K | 84.00 K | 28.00 K | 53.00 K | 152.00 K | 94.00 K |
| Gross Profit | 766.00 K | 479.00 K | 210.00 K | 213.00 K | 270.00 K | 103.00 K |
| SG&A Expense | 2.92 M | 2.72 M | 2.23 M | 1.73 M | 1.52 M | 1.57 M |
| R&D Expense | 1.20 M | 1.23 M | 1.50 M | 1.69 M | 1.43 M | 1.64 M |
| Operating Expenses | 3.97 M | 3.95 M | 3.73 M | 3.41 M | 2.95 M | 3.21 M |
| Operating Income | -3.21 M | -3.47 M | -3.52 M | -3.20 M | -2.68 M | -3.11 M |
| Pretax Income | -2.91 M | -3.52 M | -2.94 M | -2.91 M | -2.90 M | -2.42 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -2.91 M | -3.52 M | -2.94 M | -2.91 M | -2.90 M | -2.42 M |
| EPS (Basic) | -0.06 | -0.09 | -0.08 | -0.08 | -0.08 | -0.08 |
| EPS (Diluted) | -0.06 | -0.09 | -0.08 | -0.08 | -0.08 | -0.08 |
| Shares Outstanding | 47.30 M | 38.03 M | 35.33 M | 36.65 M | 36.58 M | 31.40 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.